Enumeral Biomedical
closedEnumeral Biomedical uses a nanotechnology-enabled process for therapeutic discovery, immune profiling and personalized medicine.
Launch date
Employees
Market cap
-
Enterprise valuation
€7—11m (Dealroom.co estimates May 2014.)
New York City New York (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
| N/A | $2.0m | Series A | |
| N/A | $2.3m | Early VC | |
| N/A | $1.5m | Early VC | |
| N/A | $635k | Debt | |
| N/A | $2.0m | Early VC | |
$21.5m | Post IPO Equity | ||
| N/A | N/A | IPO | |
| N/A | $3.0m | Post IPO Debt | |
| Total Funding | €7.1m | ||
Related Content
Recent News about Enumeral Biomedical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.